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Abstract: Recent advances in understanding of the mode of action of tetrahydrocannabinol and related cannabinoid in-
gredients of marijuana, plus the accumulating anecdotal reports on potential medical benefits have spurred increasing re-
search into possible medicinal uses of cannabis. Recent clinical trials with smoked and vaporized marijuana, as well as 
other botanical extracts indicate the likelihood that the cannabinoids can be useful in the management of neuropathic pain, 
spasticity due to multiple sclerosis, and possibly other indications. As with all medications, benefits and risks need to be 
weighed in recommending cannabis to patients. We present an algorithm that may be useful to physicians in determining 
whether cannabis might be recommended as a treatment in jurisdictions where such use is permitted.  
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INTRODUCTION 
  In this article we review evidence that cannabis may be 
useful as medicine. We discuss potential indications for its 
use and provide an algorithm to guide medicinal cannabis 
recommendations. 
  The reasons for a revival of interest in medicinal canna-
bis are multiple, and beyond the scope of this review, but 
include increasing anecdotal and clinical study reports of 
potential benefit, advances in understanding of the endocan-
nabinoid signaling system upon which cannabis acts, as well 
as growing public acceptance that cannabis should be avail-
able as a medicine if a physician recommends it. 
BRIEF REVIEW OF PAST CLINICAL STUDIES ON 
MEDICINAL CANNABINOIDS 
  As recently as a decade ago a review of the world litera-
ture on the status of the efficacy and safety of cannabinoids 
for pain and spasticity revealed that only nine randomized 
studies of acceptable quality had been conducted [1]. All of 
these were single dose studies comparing oral synthetic THC 
(or cannabinoid analogs or congeners) to codeine or placebo. 
Two were “N of 1” randomized trials and two were of very 
small samples of acute post-operative pain. The remaining 
trials primarily addressed chronic cancer-related pain. Taken 
as a group it appeared that oral cannabinoids (e.g., THC 
10mg) outperformed placebo and were analgesically equiva-
lent to codeine 60mg; higher doses (THC 20mg) were com-
parable to codeine 120mg, but had a much higher incidence 
of adverse effects, particularly sedation [2]. Authoritative 
reviews judged cannabinoids as being unlikely to have a role 
in acute pain management, but suggested there was enough 
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evidence for efficacy in chronic neuropathic pain and muscle 
spasticity to warrant further research [1]. 
RECENT STUDIES ON MEDICINAL CANNABIS 
  In the past decade, the scope and rigor of research has 
increased dramatically. This research has employed canna-
bis, cannabis-based extracts, and synthetic cannabinoids de-
livered by smoking, vaporization, oral, and sublingual or 
mucosal routes.  
Studies on Smoked Cannabis 
  Smoking cannabis provides rapid and efficient delivery 
of THC to brain. THC can be detected immediately in 
plasma after the first puff of a cigarette; peak concentrations 
occur within 10 minutes, then decrease to approximately 
60% of peak by 15 minutes and 20% of peak by 30 minutes, 
but there can be wide inter-individual variation in concentra-
tions achieved [3]. Rapid onset and predictable decay means 
that self-titration of dosing is attainable.  
Chronic Pain 
  A series of randomized clinical trials at the University of 
California Center for Medicinal Cannabis Research (CMCR) 
investigated the short-term efficacy of smoked cannabis for 
neuropathic pain. Sponsored by the State of California 
Medical Marijuana Research Act of 1999, and conducted 
under the auspices of the Department of Health and Human 
Services, the National Institute on Drug Abuse, and the Food 
and Drug Administration, this research allocated participants 
to smoke cannabis cigarettes containing from 1% to 8% 
THC by weight (4 to 32 mg THC) or to placebo cannabis 
cigarettes from which THC had been extracted. The total 
daily dose of THC ranged from 4 mg to 128 mg. Two trials 
enrolled patients with painful HIV peripheral neuropathy [4, 
5]; one consisted of mixed neuropathic pain due to periph-
eral or central dysfunction of the nervous system (i.e., com-Medical Marijuana: Clearing Away the Smoke  The Open Neurology Journal, 2012, Volume 6    19 
plex regional pain syndrome, peripheral neuropathy, and 
traumatic focal nerve or spinal cord injury) [6]. Patients were 
allowed to continue their usual regimen of analgesics. Re-
sults consistently indicated that cannabis significantly re-
duced pain intensity, with patients reporting 34%-40% de-
crease on cannabis compared to 17-20% on placebo. More-
over a significantly greater proportion of individuals re-
ported at least 30% reduction in pain on cannabis (46%-
52%) compared to placebo (18%-24%) [4-6], which is rele-
vant since 30% decrease in pain intensity is generally associ-
ated with reports of improved life quality [7]. The number 
needed-to-treat to achieve a 30% reduction in pain intensity 
was 3.5-4.5, a range achieved by standard non-opioid anal-
gesics (i.e., noradrenergic antidepressants and anticonvul-
sants). Interestingly “medium” dose cannabis cigarettes 
(3.5% THC) were as effective as higher dose (7% THC) [6]. 
In this same vein, a fourth trial employing an experimental 
model of neuropathic pain (intradermal injection of capsai-
cin) in healthy volunteers suggested that there may be a 
“therapeutic window” or optimal dose for smoked cannabis: 
low dose cigarettes (2% THC) had no analgesic effect, high 
dose (8%) was associated with reports of significant pain 
increase, and medium dose cannabis cigarettes (4% THC) 
provided significant analgesia [8]. Separately, another recent 
placebo-controlled, cross-over study of neuropathic pain due 
to surgery or injury examined the effect of 25 mg doses of 
smoked cannabis at various potencies (2.5%, 6%, and 9.4% 
THC by weight), administered three times daily for 14 days 
[9]. Results suggested that although lower potency dosing 
was ineffective, 9.4% THC produced modest but significant 
analgesic effects compared to placebo, in a sample selected 
for failure to respond to conventional therapy.  
Studies of Oral Preparations.  
  Oral preparations are available as synthetic THC (dron-
abinol, Marinol
R) and a synthetic analog of THC (nabilone, 
Cesamet
R). Absorption from the gut is slower and exhibits a 
delayed peak plasma concentration compared to smoking 
with bioavailability ranging from about 5-20% of dose; peak 
concentrations occur 1-6 hours after ingestion, with a magni-
tude approximately 10% of that achieved with smoking [3]. 
Chronic Pain 
  Most research using oral preparations has targeted neuro-
pathic pain and spasticity associated with multiple sclerosis 
(MS). These randomized trials suggest that dronabinol (up to 
25 mg daily) significantly reduces pain compared to placebo 
(50% “improved” on dronabinol compared to 30% on pla-
cebo, p < .05) [10], with a number-needed-to-treat for 50% 
pain reduction of 3.5, which is in the range of efficacy ob-
served for standard non-opioids [11]. Effects on spasticity 
are mixed: there may be no observable change in examiner-
rated muscle tone, but patients report significant relief [10]. 
  There is less research with nabilone, although one three-
week randomized crossover trial reported that nabilone 2mg 
provided modest analgesia, comparable to dihydrocodeine 
240mg daily in neuropathic pain [12]. 
Nausea-Emesis and Appetite Stimulation 
Although serotonin receptor (5 HT3) antagonists (e.g., on-
dansetron, Zofran
R) and Substance P/neurokinin-1 (NK-1) 
receptor antagonists (e.g., aprepitant, Emend
R) are the main-
stays for treatment, dronabinol and nabilone are also FDA-
approved for control of acute and delayed nausea and emesis 
due to cancer chemotherapy. Meta-analyses indicate these 
cannabinoids are equivalent to or more effective than meto-
clopraminde and neuroleptics, but their side effect profile is 
less favorable in terms of sedation, dizziness, dysphoria, 
hypotension, and anxiety [13, 14]. There are no head-to-head 
comparisons of cannabinoids with serotonin 5 HT3 receptor 
or Substance P/NK-1 receptor antagonists. 
  Anorexia, early satiety, weight loss and cachexia are 
prevalent in late stage cancer and advanced HIV disease, but 
there are few effective treatments. Trials in AIDS patients 
with clinically significant weight loss indicated that dronabi-
nol 5mg daily significantly outperformed placebo in terms of 
short term appetite enhancement (38% vs. 8% at 6 weeks), 
and that these effects persisted for up to 12 months [15, 16], 
but were not accompanied by significant differences in 
weight gain, perhaps because of disease-associated energy 
wasting. The major practical limitations are the accompany-
ing psychoactive side effects, and the problems of oral ad-
ministration (eg, delayed onset of action, variable absorption, 
extended duration of effects). 
Studies on Cannabis-based Extracts 
  Outside the US, extracts of whole plant are licensed and 
available in capsules (Cannador
R), with the main constituents 
being THC and the non-psychoactive plant cannabinoid, 
cannabidiol, in a ratio of 2:1. Rectal suppositories are also 
used to deliver THC hemisuccinate. Several small to me-
dium-sized, randomized, controlled trials in MS suggest im-
provements in pain and perceived spasticity at daily doses of 
THC ranging from 7.5mg to 27.5mg [10, 17, 18]. In some 
trials [19] but not others [10, 20] observer-assessed spasticity 
also improved.  
Studies with Alternative Delivery Systems 
  The hazards of smoking and the pharmacokinetic limita-
tions of ingestion of cannabinoids has led to a search for 
alternative systems of administration. One alternative is de-
vices which vaporize cannabis leaves by heating the plant 
product to below the temperature of combustion (175-225 
degrees C), permitting inhalation of volatilized gases minus 
hazardous pyrroles produced by burning. Preliminary work 
using plant material with a range of THC content (e.g., 1-7% 
THC) suggests that there is rapid onset, with peak concentra-
tions and six-hour area under the plasma concentration 
curves comparable to those achieved by smoking [21]. Va-
porization is not a perfect solution since carbon monoxide is 
formed, but levels are significantly lower than with smoking 
[21]. Clinical trials are currently in progress at the CMCR 
assessing the efficacy of vaporized cannabis as an analgesic 
in chronic neuropathic pain.  
  Sublingual delivery systems of whole cannabis plant ex-
tract, which employ metered spray devices to deliver meas-
ured doses of THC (2.7mg) and cannabidiol (2.5mg), are 
undergoing Phase IIb/III trials in the US, and are licensed 
elsewhere for cancer pain and multiple sclerosis-associated 
neuropathic pain and spasticity (nabiximols, Sativex
R). The 
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concentrations, predetermined dosing aliquots, and time-out 
systems which may help prevent overuse. Some placebo-
controlled trials suggest significant analgesia in neuropathic 
pain due to multiple sclerosis [22] and mixed neuropathy 
(e.g., post-herpetic, traumatic, vascular neuropathies, [23] 
but others do not [20]. Other controlled trials suggest effi-
cacy for cancer-related pain inadequately responsive to 
opioid analgesia [24]. Responders participating in the open 
label extension phases of controlled trials appear to maintain 
analgesia on one-year follow-up [23].  
  In regard to spasticity in multiple sclerosis, a recent 
meta-analysis combining three trials with nabiximols in over 
600 patients noted that mean intensity of patient rated spas-
ticity was significantly reduced compared to placebo [20, 25, 
26], and that the proportion of “responders” (30% reduction) 
was also significantly greater, with about 37% on the can-
nabinoid compared to 26% on placebo experiencing relief. 
Those reporting relief of spasticity seemed to maintain their 
gains over one year follow-up [27]. As with other studies 
noted above, observer-rated spasticity is often not reduced 
[20, 25, 28]; however, a recent CMCR study did find a sig-
nificant reduction in observed spasticity among those admin-
istered active smoked marijuana vs. placebo marijuana [58]. 
PRESERVATION OF MASKING IN CLINICAL   
TRIALS 
  Because of the acute psychoactive effects of the experi-
mental agent there is understandable concern that blinding 
cannot be preserved in placebo-controlled clinical trials of 
cannabinoids, particularly with cross-over designs. Few stud-
ies assess masking, but two cross-over trials tested mainte-
nance of the blind by asking participants to “guess” assign-
ment at different points of the study. Results suggest that 
participants, whether they are naïve or experienced cannabis 
users, are in the first week of a trial no more likely than by 
chance to guess assignment [5, 9]. With continued exposures 
rates of correct guesses exceed 75%, but exceed chance only 
in a high potency arm (9%) [9]. In another study correct 
guessing was related to two factors: whether the subject re-
ceived placebo or cannabis first; and when during the study 
the participant guessed assignment [5]. Among individuals 
randomized to receive placebo first, guessing was no better 
than chance through the end of the first treatment week, 
whereas the majority of those randomized to receive canna-
bis first correctly guessed their treatment assignment at all 
time points. Furthermore, by the conclusion of the study, 
when all subjects had been given the opportunity to compare 
the cannabis placebo and treatments, even those randomized 
to receive placebo first correctly guessed their treatment as-
signment [5]. This raised the possibility that some of the pain 
reduction was placebo driven. Secondary analyses to assess 
whether correct treatment guessing influenced treatment re-
sponses showed that in the placebo group during the first 
treatment week, when guessing was no better than chance, 
cannabis still provided pain relief superior to that of placebo. 
This finding suggests that although placebo effects were pre-
sent, treatment effects were independent [5]. 
RISKS AND MANAGEMENT OF MEDICINAL USE 
OF CANNABINOIDS 
  Acutely and over the longer term cannabis may have un-
wanted systemic and psychoactive adverse effects that must 
be taken into consideration in chronic pain populations, who 
have high rates of co-occurring medical illness (eg, cardio-
vascular disease) and co-morbid psychiatric and substance 
use disorders. In general these effects are dose-related, are of 
mild to moderate severity, appear to decline over time, and 
are reported less frequently in experienced than in naïve us-
ers. Reviews suggest the most frequent side effects are dizzi-
ness or lightheadedness (30%-60%), dry mouth (10%-25%), 
fatigue (5%-40%), muscle weakness (10%-25%), myalgia 
(25%), and palpitations (20%) [17]. Cough and throat irrita-
tion are reported in trials of smoked cannabis [9]. Tachycar-
dia and postural hypotension are infrequent but caution is 
warranted in patients with cardiovascular disease, and possi-
bly younger adults who intend to embark on very vigorous 
physical activity. At higher doses, sedation and ataxia with 
loss of balance are frequent. Participants in some but not all 
studies report euphoria: the relative absence of psychoactive 
effect has been attributed to the observation that plasma con-
centrations obtained in clinical trials are often <25% of those 
achieved by “recreational” users (eg, 25ng/ml vs >100ng/ml) 
[9]. After repeated smoked or oral marijuana doses, tolerance 
is rapidly acquired (in two to 12 days) to many of its adverse 
effects, e.g., cardiovascular, autonomic, and many subjective 
and cognitive effects [29]. After exposure is stopped, toler-
ance is lost with similar rapidity.  
  There is little systematic data on timeline to tolerance of 
either adverse or therapeutic effects, like analgesia. Concerns 
have long been voiced that rapid tolerance to adverse effects 
might portend tolerance to beneficial effects [29]. Data from 
studies using oral sprays of cannabinoids or dronabinol in 
multiple sclerosis report that individuals can reduce the inci-
dence and severity of adverse effects by downward self-
titration without loss of analgesia [17]. Other studies in this 
population note that overall the incidence and severity of 
adverse effects diminishes over time without evidence of 
tolerance to analgesic effects [20, 22]. Yet it is rare that 
clinical trials of cannabinoids extend follow-up beyond 12 
weeks, leaving questions on maintenance of gains or need 
for dose escalation unanswered [10, 26]. One study with 12-
month follow-up concluded there may be sustained analgesia 
for pain associated with multiple sclerosis, where about 30% 
of cannabinoid-treated participants report continued “im-
provement” at 12 months compared to about 15% on placebo 
[30] on doses conservatively limited to a maximum of 25mg 
THC daily. This suggests that pain relief may be sustained 
without dose increases. But the study design was not in-
tended to determine the proportion of patients who experi-
enced diminution of effect, or whether dose escalation, even 
within the set boundary, was needed for maintenance of effi-
cacy.  
  There are risks to be considered in assessing the potential 
of cannabinoid therapeutics. Cannabis, like other analgesics, 
can be associated with dependence and a withdrawal syn-
drome, occurring in a dose-dependent fashion [29]. Under 
controlled conditions in healthy, experienced users of mari-
juana, withdrawal from a “low” daily dose (ie, oral THC 10 
mg every 3-4 hours for 5-21 days) commences within 12 
hours, is diminished by 24 hours, and is complete in 48 to 72 
hours [29]. Other short term experiments with oral THC (20 
to 30mg four times daily) and smoked cannabis (1% and 3% 
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drome characterized by anxiety, irritability-restlessness, in-
somnia, stomach pain and decreased appetite [31, 32], with 
mood effects more prominent at the higher dosages. In re-
search specifically designed to establish the time line of ab-
stinence among regular heavy users (4 cigarettes daily), 
symptoms peak at 2 to 3 days, and persist for up to 2 weeks, 
although sleep disturbance may continue for up to 6 weeks 
[33]. In light of abstinence effects, standard practice in clini-
cal trials administering a maximum of 25 mg THC daily is to 
use a tapering scheme to conclude therapy, with a 20% per 
day dose reduction [30]. Patients discontinuing higher dose 
cannabinoids for analgesia might warrant a longer tapering 
regimen, but this has not been studied. 
  Fatal overdose with cannabis alone has not been reported. 
In terms of acute drug interactions, additive effects of canna-
bis, anticholinergics, and CNS depressants should expected 
(e.g., increased sedation, dizziness, dry mouth, confusion). 
Cannabinoids are metabolized by several enzyme systems, 
including Cytochrome P450 (CYP 2C9, CYP 3A4) and can 
induce or inhibit CYP 3A4, but there is little evidence of 
important drug-drug interactions based on CYP 450 systems. 
Smoking itself (e.g., cannabis or tobacco) induces CYP 1A2, 
and may increase clearance of some antipsychotics (e.g., 
olanzapine, clozapine) and antidepressants (e.g., some tri-
cyclics, mirtazepine) [34, 35]. Overall then, the acute medi-
cal risks of THC as used in clinical trials are rather low. 
  There can be adverse psychiatric side effects. THC in-
toxication and euphoria can be disturbing, particularly to 
elderly patients. Anxiety and panic attacks occur, as do frank 
psychotic reactions (principally paranoia), as well as so-
called “paradoxical” effects of dysphoria, dejection, and de-
pressed mood [36, 37]. Although unlikely to be a factor in 
the application of cannabinoids for pain, there is concern that 
early adolescent use of cannabis may heighten later risk of 
psychosis [36, 38], and evidence that genetic variation (sin-
gle nucleotide polymorphisms) heightens vulnerability [39]. 
  Acute cannabinoid intoxication adversely impacts proc-
essing speed, attention, learning and recall, perception of 
time and velocity, reaction time and psychomotor abilities in 
a dose-dependent fashion [40]. Formal neuropsychological 
testing in clinical trials reveals mild impairment at usual an-
algesic doses [6, 23]. While cannabis can acutely impair 
skills required to drive motor vehicles in a dose-related fash-
ion, epidemiological data are inconclusive with regard to the 
association of traffic accidents and use of cannabis [41]. 
There is speculation that cannabis use is associated with in-
creased awareness of impairment (e.g., altered perception of 
time and speed), which results in compensatory behavioral 
strategies. What is clearer from experimental and epidemi-
ologic data is that driving under the influence of both alcohol 
and cannabis in combination confers greater risk of accidents 
than the risk of either drug alone [41]. 
  The longer-term health risks of cannabis are unclear, and 
the evidence is based on non-medical use [42]. Long-term 
use of inhaled cannabis may be associated with dependence 
and increased respiratory symptoms; but some epidemiologi-
cal studies have not found more lung disease in long-term 
users, once the effects of tobacco are accounted [43]. Long-
term use of inhaled cannabis has not been associated with 
increased risk of lung or gastrointestinal cancers [44], al-
though a meta-analysis found evidence of premalignant 
changes in the respiratory tract [45]. There is some evidence 
that among individuals with pre-existing cardiac disease, 
cannabis users have an increased risk of myocardial infarc-
tion in the hour after smoking cannabis compared to non-
users [46]. A recent meta-analysis showed no major residual 
effects on neurocognitive functioning in long term daily-
users of cannabis [47]. THC rapidly crosses the placenta and 
accumulates in breast milk of nursing mothers [3], but there 
is no systematic evidence of direct or behavioral teratogenic-
ity. 
  In reviewing the possible acute and long term adverse 
effects of cannabinoids as therapeutic agents one needs also 
to be mindful that other agents that are used for treatment of 
pain or spasticity also have adverse effects. Opioids produce 
sedation, nausea, constipation and dependence, withdrawal 
from which results in serious abstinence syndrome with 
much more severe effects – e.g. severe autonomic, gastroin-
testinal, and psychiatric – than the rather mild cannabis 
withdrawal phenomena. Tricyclic antidepressants and an-
tiepileptic drugs commonly prescribed for chronic pain have 
psychotropic (e.g. sedation), anticholinergic (e.g. constipa-
tion, dizziness, palpitations, visual disturbance, urinary re-
tention), and neuromuscular effects. Drugs for spasticity 
produce sedation (e.g. baclofen), hypotension (e.g. tiza-
nidine) and serious interactions with antibiotics (e.g. tiza-
nidine and ciprofloxacin). Benzodiazepines that are some-
times prescribed for spasticity can produce sedation, psy-
chomotor incoordination, memory lapses, and paradoxical 
reactions, as well as dependence and withdrawal syndromes. 
Opioids and sedative-hypnotics are also drugs of abuse, and 
their ability to induce physiological dependence and serious 
withdrawal states exceed those of cannabis. Therefore, 
judgements on relative benefits and risks of cannabinoids as 
medicines need to be viewed within the broader context of 
risk-benefit of other agents as well [48]. 
PATIENT SELECTION FOR CANNABINOID THER-
APY 
  Oral THC (eg, dronabinol) is FDA-approved as a second 
line agent for chemotherapy-associated nausea and emesis, 
and appetite stimulation. Dronabinol (and nabilone) have 
some evidence of efficacy for chronic neuropathic pain; 
whole plant cannabis extracts delivered by capsule or oral-
mucosal spray has been approved in Europe for analgesia in 
neuropathic pain and control of painful muscle spasticity. 
Patient selection for these agents would seem to be rather 
straightforward, and focus on therapeutic response to con-
ventional treatments, consideration of possible psychotropic 
(eg, sedation effects if combined with alcohol) and cardio-
vascular effects, risk of dependence and an abstinence syn-
drome, and acknowledgement that there is narrow empirical 
basis for efficacy compared to standard treatments. Patients 
should be educated about expected adverse effects. The 
pharmacokinetics of orally administered cannabinoids would 
seem to decrease likelihood of diversion or abuse. 
On the other hand, prescription of inhaled cannabis for 
medical purposes is legal in some US jurisdictions, and neu-
rologic consultants, who are likely to be asked about the ad-
visability of prescribing or recommending “medical mari-22     The Open Neurology Journal, 2012, Volume 6   Grant et al. 
juana,” may be justifiably uncertain of how to proceed. 
There are no published consensus statements or systematic 
approaches to identify candidates for “medical marijuana” or 
guide treatment; although some regulatory agencies, such as 
the Medical Board and the Office of the Attorney General of 
California have proposed guidelines (Table 1).  
  It should be noted that the evidence for efficacy is based 
primarily on relatively few short-term studies with small 
sample sizes of selected, mostly neuropathic pain conditions 
(ie, Phase II/III trials). “Medical cannabis”, now available 
from dispensaries in some jurisdictions, is not subject to 
governmental standardization, and its constituents and po-
tency are consequently unknown. Moreover, the mean po-
tency of marijuana seized by federal and state authorities has 
more than doubled over the past 15 years to about 6% THC, 
well over 20% of confiscated plants have a potency exceed-
ing 9%, and some specimens exceed 25% THC [49]. Thus, 
cannabis obtained from dispensaries or other sources may 
have potency far exceeding that used in clinical trials de-
scribed in this review. Furthermore, cannabis elicits concerns 
among regulators, clinicians, and patients regarding issues of 
misuse, abuse, and other liabilities. With these facts in mind, 
a potentially useful framework for evaluating advisability of 
medical marijuana are guidelines released by professional 
pain societies concerning prescription of long-term opioid 
therapy for chronic, non-cancer pain [50, 51]. The guidelines 
are framed by several questions. One question regards not 
only the legality of cannabis, but the standard of practice in 
the clinician’s community, since either prescription or rec-
ommendation for use of cannabis is outside of “conventional 
practice.” As with prescription of opioids there are potential 
issues of legal liability [52]. A second question asks whether 
other treatments offer a more favorable risk-benefit ratio. 
The answer depends upon a careful differential diagnosis, 
identification of a potentially responsive pain syndrome 
(e.g., the strongest evidence is for neuropathic pain), consid-
eration of other approaches (e.g., disease-modifying treat-
ment, ablative interventions, other analgesics like anticon-
vulsants, noradrenergic antidepressants, opioids, or non-
steroidals, and cognitive-behavioral or rehabilitative therapy, 
or complementary treatments). A third question is whether 
there are medical and psychiatric risks. The shorter-term 
medical risks of cannabis are relatively low overall. Risks of 
hypotension and tachycardia should be evaluated in patients 
with cardiovascular diseases, as these may be associated 
with elevated risk of cannabis-associated myocardial infarc-
tion. Elderly patients with neurocognitive impairment may 
be predisposed to adverse effects of cannabis on memory and 
concentration, while even intact older individuals may be 
susceptible to over-sedation, and falls due to ataxia. The in-
toxicating effects of cannabis may be disturbing. A history of 
severe anxiety or paranoia on prior exposure to cannabis 
should be sought and would be a contraindication; since pa-
tients with serious mental illness (bipolar disorder or schizo-
phrenia) may be particularly vulnerable to these adverse ef-
fects, they are unlikely to be candidates.  
  Moreover, there must be assessment of the potential for 
misuse, abuse, or addiction. This requires a careful examina-
tion for history of substance use disorders, and psychiatric 
illness, perhaps supplemented by formal psychiatric consul-
tation. Screening questionnaires, such as the Screener and 
Opioid Assessment for Patients with Pain (SOAPP-R) [53], 
have been validated in chronic pain clinic populations to 
stratify patients into “lower” or “higher” risk of future 
opioid-related aberrant behaviors, and suitably modified 
might be applicable to assessment of risks for cannabis mis-
use. Most pain experts consider sobriety a foundation of suc-
cessful pain treatment. Cannabis use is prevalent in chronic 
pain patients prescribed opioids and may be associated with 
current or future opioid misuse [54]. Patients screened “at 
risk” for aberrant opioid use, or a history of cannabis or other 
substance use disorders usually would not be considered 
eligible for medicinal cannabis. There might be exceptions. 
For example, there is some evidence that patients with sus-
tained remission from alcohol dependence (ie, sober for > 5 
years) are at no greater risk for developing a new onset sub-
stance abuse problem than non-alcohol controls, so this 
population would not necessarily be excluded automatically 
[55]. Also, a recent randomized trial suggests highly-
structured approaches may result in successful analgesia and 
restoration of function without aberrant opioid use in “high 
risk” patients prescribed opioids for chronic pain [56]. Such 
methods, which involve a regimen of systematic urine toxi-
cology testing, use of compliance checklists to evaluate for 
“red flags” of non-adherence to the program (eg, unsanc-
tioned dose escalations, illicit drug use), and enrollment in a 
substance misuse counseling [56], might be adapted for use 
in high-risk candidates for medical marijuana. Before em-
barking on a trial of medical marijuana in patients with prior 
history of substance use disorders, it would be prudent to 
Table 1.  Medical Board/Office of the Attorney General of California Guidelines for Medical Marijuana 
Physicians Recommending Medical Marijuana Need to: 
1  Take a history and conduct a good faith examination of the patient; 
2  Develop a treatment plan with objectives; 
3  Provide informed consent, including discussion of side effects; 
4  Periodically review the treatment’s efficacy; 
5  Obtain consultations, as necessary; and 
6  Keep proper records supporting the decision to recommend the use of medical marijuana. 
http://www.mbc.ca.gov/board/media/releases_2004_05-13_marijuana.html 
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establish a similar routine of urine toxicology testing, com-
pliance checklists, and co-enrollment in a formal substance 
abuse treatment facility, just as is recommended for a trial of 
opioid analgesics [52]. Finally, chronic pain may be associ-
ated with major depression, which complicates treatment, 
and which must be diagnosed and independently treated for 
successful pain management. All of these factors being con-
sidered, if the decision is made to proceed, the clinician must 
formulate and document a treatment plan and the patient’s 
agreement to abide by whatever guidelines are established. 
The clinical “trial” would entail establishing a therapeutic 
“dose,” appropriately monitoring for adverse effects and 
misuse, and assessing outcome in terms of pain, mood, and 
function. Based on the literature of efficacy in neuropathic 
pain, there could be evidence of an effect within a minimum 
of two weeks. Response rates have been noted to increase, 
however, between two and four weeks in previous neuro-
pathic pain registration trials for gabapentin and duloxetine 
[57]; one might select a longer duration in difficult-to-treat 
cases. Considering all these factors, one would then decide 
with the patient whether continued treatment is warranted. A 
possible algorithm to guide physician decision-making is 
presented in Fig. (1). 
CONCLUSION 
  Evidence is accumulating that cannabinoids may be use-
ful medicine for certain indications. Control of nausea and 
vomiting and the promotion of weight gain in chronic inani-
tion are already licensed uses of oral THC (dronabinol cap-
 
Fig. (1). A decision tree approach for physicians who may be considering recommending medicinal cannabis to a patient. This decision tree 
suggests some key points that a physician may need to consider in making his/her determination. In this case, a patient is assumed to present 
with persistent neuropathic pain. Initially, a determination needs to be made that the patient’s signs and symptoms are indeed consistent with 
this diagnosis. Assuming a patient does not respond favorably to more standard treatments (e.g., antidepressants, anticonvulsants, etc), or 
cannot tolerate those, and the patient is willing to consider medicinal cannabis, the physician needs to determine risk versus benefit. Among 
these considerations is whether there is a history of substance abuse or serious psychiatric disorder that might be exacerbated by medicinal 
cannabis. Even if such risks exists, this does not necessarily preclude the use of medicinal cannabis; rather coordination with appropriate 
substance abuse and psychiatric resources is necessary, and based on such consultation a risk benefit ratio can be determined. In patients in 
whom the ratio appears favorable, the physician needs to discuss alternative modes of cannabis administration which may include oral, 
smoked, or vaporized systems. Once risks and benefits are evaluated and discussed with the patient, cannabis treatment may commence as 
with other psychotropic medications, with attention being paid to side effects as well as efficacy. In addition, there needs to be attentiveness 
to potential for misuse and diversion, which can then trigger a decision to discontinue. 
Key 
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3.  For example, at least 30% reduction in pain intensity. 
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5.  Determine history of substance abuse. If yes, or at “high risk” aberrant for drug behavior; proceed with close observation; possibly coor-
dinate with substance abuse treatment program. 
6.  Efficacy = at least 30% reduction in pain intensity.  
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sules). Recent research indicates that cannabis may also be 
effective in the treatment of painful peripheral neuropathy 
and muscle spasticity from conditions such as multiple scle-
rosis [58]. Other indications have been proposed, but ade-
quate clinical trials have not been conducted. As these thera-
peutic potentials are confirmed, it will be useful if marijuana 
and its constituents can be prescribed, dispensed, and regu-
lated in a manner similar to other medications that have psy-
chotropic effects and some abuse potential. Given that we do 
not know precisely which cannabinoids or in which combi-
nations achieve the best results, larger and more representa-
tive clinical trials of the plant product are warranted. Be-
cause cannabinoids are variably and sometimes incompletely 
absorbed from the gut, and bioavailability is reduced by ex-
tensive first pass metabolism, such trials should include de-
livery systems that include smoking, vaporization, and oral 
mucosal spray in order to achieve predictable blood levels 
and appropriate titration. Advances in understanding the 
medical indications and limitations of cannabis in its various 
forms should facilitate the regulatory and legislative proc-
esses. 
  The classification of marijuana as a Schedule I drug as 
well as the continuing controversy as to whether or not can-
nabis is of medical value [59] are obstacles to medical pro-
gress in this area. Based on evidence currently available the 
Schedule I classification is not tenable; it is not accurate that 
cannabis has no medical value, or that information on safety 
is lacking. It is true cannabis has some abuse potential, but 
its profile more closely resembles drugs in Schedule III 
(where codeine and dronabinol are listed). The continuing 
conflict between scientific evidence and political ideology 
will hopefully be reconciled in a judicious manner [60, 61]. 
In the meantime, the decision to recommend this treatment in 
jurisdictions where use of medical marijuana is already per-
mitted needs to be based on a careful assessment that in-
cludes proper diagnosis of a condition for which there is evi-
dence that cannabis may be effective, along with considera-
tion as to response to more standard treatments. Prior sub-
stance abuse history, psychiatric comorbidity, and other fac-
tors need to be weighed in a risk benefit analysis. Part of this 
analysis should consider that the potential longer-term harms 
of the cannabinoids are not fully understood: these include 
abuse and a dependence syndrome, adverse psychiatric and 
medical effects in vulnerable populations, and documented 
risk to traffic safety when combined with alcohol, and per-
haps singly [62]. In the long term, as further studies demon-
strate whether cannabis is effective for various indications, 
this should lead to development of novel modulators of the 
endocannabinoid system which may be prescribed and used 
as more traditional medicines. 
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